• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ncRNA 介导的 LPCAT1 高表达与肝癌的不良预后和肿瘤免疫浸润相关。

ncRNA-Mediated High Expression of LPCAT1 Correlates with Poor Prognosis and Tumor Immune Infiltration of Liver Hepatocellular Carcinoma.

机构信息

Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang Province, China.

College of Pharmacy, Xiangnan University, Chenzhou, China.

出版信息

J Immunol Res. 2022 May 16;2022:1584397. doi: 10.1155/2022/1584397. eCollection 2022.

DOI:10.1155/2022/1584397
PMID:35615532
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9126685/
Abstract

PURPOSE

To investigate the expression of LPCAT1 in liver hepatocellular carcinoma (LIHC) and its relationship with prognosis and immune infiltration and predict its upstream nonencoding RNAs (ncRNAs).

METHOD

In this study, expression analysis and survival analysis for LPCAT1 in pan cancers were first performed by using The Cancer Genome Atlas (TCGA) data, which suggested that LPCAT1 might be a potential LIHC oncogene. Then, ncRNAs contributing to the overexpression of LPCAT1 were explored in starBase by a combination of expression analysis, correlation analysis, and survival analysis. Immune cell infiltration of LPCAT1 in LIHC was finally investigated via Tumor Immune Estimation Resource (TIMER).

RESULT

SNHG3 was observed to be the most promising upstream lncRNA for the hsa-miR-139-5p/LPCAT1 axis in LIHC. In addition, the LPCAT1 level was significantly positively associated with tumor immune cell infiltration, biomarkers of immune cells, and immune checkpoint expression in LIHC.

CONCLUSION

To summarize, the upregulation of LPCAT1 mediated by ncRNAs is associated with poor prognosis, immune infiltration, and immune checkpoint expression in LIHC.

摘要

目的

研究 LPCAT1 在肝肝细胞癌（LIHC）中的表达及其与预后和免疫浸润的关系，并预测其上游非编码 RNA（ncRNA）。

方法

本研究首先利用癌症基因组图谱（TCGA）数据对 LPCAT1 在泛癌中的表达进行分析和生存分析，提示 LPCAT1 可能是 LIHC 的潜在癌基因。然后，通过表达分析、相关性分析和生存分析相结合，在 starBase 中探索导致 LPCAT1 过表达的 ncRNA。最后，通过肿瘤免疫估计资源（TIMER）研究 LPCAT1 在 LIHC 中的免疫细胞浸润。

结果

在 LIHC 中，SNHG3 被观察到是 hsa-miR-139-5p/LPCAT1 轴最有前途的上游 lncRNA。此外，LPCAT1 水平与 LIHC 中的肿瘤免疫细胞浸润、免疫细胞标志物和免疫检查点表达显著正相关。

结论

总之，ncRNA 介导的 LPCAT1 上调与 LIHC 中的不良预后、免疫浸润和免疫检查点表达相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9126685/3d60ae3aa93d/JIR2022-1584397.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9126685/0deeb17a420e/JIR2022-1584397.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9126685/c4e841d9999c/JIR2022-1584397.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9126685/bfb040320f56/JIR2022-1584397.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9126685/7a8ac8bd21f6/JIR2022-1584397.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9126685/895d750c90e9/JIR2022-1584397.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9126685/ddd90eea759a/JIR2022-1584397.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9126685/d4ca840a012e/JIR2022-1584397.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9126685/3d60ae3aa93d/JIR2022-1584397.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9126685/0deeb17a420e/JIR2022-1584397.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9126685/c4e841d9999c/JIR2022-1584397.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9126685/bfb040320f56/JIR2022-1584397.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9126685/7a8ac8bd21f6/JIR2022-1584397.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9126685/895d750c90e9/JIR2022-1584397.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9126685/ddd90eea759a/JIR2022-1584397.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9126685/d4ca840a012e/JIR2022-1584397.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9126685/3d60ae3aa93d/JIR2022-1584397.008.jpg

相似文献

1
ncRNA-Mediated High Expression of LPCAT1 Correlates with Poor Prognosis and Tumor Immune Infiltration of Liver Hepatocellular Carcinoma.ncRNA 介导的 LPCAT1 高表达与肝癌的不良预后和肿瘤免疫浸润相关。
J Immunol Res. 2022 May 16;2022:1584397. doi: 10.1155/2022/1584397. eCollection 2022.
2
LPCAT1 acts as an independent prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.LPCAT1 作为一个独立的预后生物标志物，与肝细胞癌中的免疫浸润相关。
Eur J Med Res. 2022 Oct 28;27(1):216. doi: 10.1186/s40001-022-00854-1.
3
ncRNA-mediated SOX4 overexpression correlates with unfavorable outcomes and immune infiltration in hepatocellular carcinoma.ncRNA 介导的 SOX4 过表达与肝细胞癌不良预后和免疫浸润相关。
BMC Gastroenterol. 2024 Aug 14;24(1):265. doi: 10.1186/s12876-024-03346-0.
4
LncRNA CARMN Affects Hepatocellular Carcinoma Prognosis by Regulating the miR-192-5p/LOXL2 Axis.长链非编码 RNA CARMN 通过调控 miR-192-5p/LOXL2 轴影响肝细胞癌预后。
Oxid Med Cell Longev. 2022 Oct 8;2022:9277360. doi: 10.1155/2022/9277360. eCollection 2022.
5
COMMD2 Upregulation Mediated by an ncRNA Axis Correlates With an Unfavorable Prognosis and Tumor Immune Infiltration in Liver Hepatocellular Carcinoma.由ncRNA轴介导的COMMD2上调与肝细胞癌的不良预后和肿瘤免疫浸润相关。
Front Oncol. 2022 Apr 29;12:853026. doi: 10.3389/fonc.2022.853026. eCollection 2022.
6
Downregulation of ZC3H13 by miR-362-3p/miR-425-5p is associated with a poor prognosis and adverse outcomes in hepatocellular carcinoma.miR-362-3p/miR-425-5p 下调 ZC3H13 的表达与肝癌患者预后不良及不良结局相关。
Aging (Albany NY). 2022 Mar 12;14(5):2304-2319. doi: 10.18632/aging.203939.
7
Knockdown of LPCAT1 Repressed Hepatocellular Carcinoma Growth and Invasion by Targeting S100A11.敲低 LPCAT1 通过靶向 S100A11 抑制肝癌生长和侵袭。
Ann Clin Lab Sci. 2023 Mar;53(2):212-221.
8
Genomic gain/methylation modification/hsa-miR-132-3p increases RRS1 overexpression in liver hepatocellular carcinoma.基因组获得/甲基化修饰/hsa-miR-132-3p 增加肝癌中 RRS1 的过表达。
Cancer Sci. 2023 Nov;114(11):4329-4342. doi: 10.1111/cas.15933. Epub 2023 Sep 13.
9
High expression of RNF31 is associated with tumor immune cell infiltration and leads to poor prognosis in liver hepatocellular carcinoma.RNF31 高表达与肿瘤免疫细胞浸润相关，并导致肝癌预后不良。
Sci Rep. 2023 Apr 28;13(1):6957. doi: 10.1038/s41598-023-32692-4.
10
Prognostic and immunological potential of PPM1G in hepatocellular carcinoma.PPM1G 在肝细胞癌中的预后和免疫潜力。
Aging (Albany NY). 2021 May 5;13(9):12929-12954. doi: 10.18632/aging.202964.

引用本文的文献

1
Nuclear respiratory factor 1 drives hepatocellular carcinoma progression by activating LPCAT1-ERK1/2-CREB axis.核呼吸因子 1 通过激活 LPCAT1-ERK1/2-CREB 轴促进肝细胞癌进展。
Biol Direct. 2023 Oct 24;18(1):67. doi: 10.1186/s13062-023-00428-z.
2
The validation and clinical significance of LPCAT1 down-regulation in acute myeloid leukemia.LPCAT1 下调在急性髓系白血病中的验证和临床意义。
Mol Biol Rep. 2023 Jun;50(6):4955-4963. doi: 10.1007/s11033-023-08449-7. Epub 2023 Apr 20.

本文引用的文献

1
[Research Progress in Immunosuppressive Tumor Microenvironment of Gastrointestinal Cancer].[胃肠道癌免疫抑制性肿瘤微环境的研究进展]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2022 Jan;53(1):7-14. doi: 10.12182/20220160501.
2
CD274 (PD-L1) Methylation is an Independent Predictor for Bladder Cancer Patients' Survival.CD274（程序性死亡受体配体1）甲基化是膀胱癌患者生存的独立预测指标。
Cancer Invest. 2022 Mar;40(3):228-233. doi: 10.1080/07357907.2022.2028805. Epub 2022 Jan 19.
3
Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?
慢性病毒性肝炎相关肝细胞癌：我们的现状如何？
Int J Mol Sci. 2022 Jan 2;23(1):500. doi: 10.3390/ijms23010500.
4
Cell Death in Hepatocellular Carcinoma: Pathogenesis and Therapeutic Opportunities.肝细胞癌中的细胞死亡：发病机制与治疗机遇
Cancers (Basel). 2021 Dec 23;14(1):48. doi: 10.3390/cancers14010048.
5
New Frontiers in the Medical Therapy of Hepatocellular Carcinoma.肝细胞癌的医学治疗新领域。
Chemotherapy. 2022;67(3):164-172. doi: 10.1159/000521837. Epub 2022 Jan 9.
6
Immunotherapy in older patients with hepatocellular carcinoma.老年肝细胞癌患者的免疫治疗
Eur J Cancer. 2022 Feb;162:76-98. doi: 10.1016/j.ejca.2021.11.024. Epub 2021 Dec 23.
7
Molecular mechanisms of thyroid cancer: A competing endogenous RNA (ceRNA) point of view.甲状腺癌的分子机制：竞争性内源 RNA（ceRNA）观点。
Biomed Pharmacother. 2022 Feb;146:112251. doi: 10.1016/j.biopha.2021.112251. Epub 2021 Dec 14.
8
LncRNA SNHG3 promotes gastric cancer cell proliferation and metastasis by regulating the miR-139-5p/MYB axis.长链非编码 RNA SNHG3 通过调控 miR-139-5p/MYB 轴促进胃癌细胞的增殖和转移。
Aging (Albany NY). 2021 Dec 13;13(23):25138-25152. doi: 10.18632/aging.203732.
9
Comprehensive Analysis of LPCATs Highlights the Prognostic and Immunological Values of in Hepatocellular Carcinoma.溶血磷脂酰胆碱酰基转移酶（LPCATs）的综合分析凸显了其在肝细胞癌中的预后和免疫价值。
Int J Gen Med. 2021 Nov 30;14:9117-9130. doi: 10.2147/IJGM.S344723. eCollection 2021.
10
Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.癌症免疫治疗中 CTLA-4 阻断的临床经验：从单特异性单克隆抗体伊匹单抗到针对肿瘤微环境的 PRObody 和双特异性分子。
Pharmacol Res. 2022 Jan;175:105997. doi: 10.1016/j.phrs.2021.105997. Epub 2021 Nov 24.